<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957550</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0302-303</org_study_id>
    <nct_id>NCT04957550</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1&#xD;
      inhibitor SHR0302 in subjects with active psoriatic arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">November 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR0302 tablets compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 response rate at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20) at week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20 response rate at week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20) at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR50/70 response rate at week 24 and week 48</measure>
    <time_frame>Week 24 and week48</time_frame>
    <description>Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 50%/70% (ACR50/70) at week 24 and week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28-CRP week 24 and week 48</measure>
    <time_frame>Week 24 and week 48</time_frame>
    <description>Change from baseline in the disease activity score-CRP(DAS 28-CRP) at week 24 and week 48</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR0302 tablets dose 1+ Placebo dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR0302 tablets dose 2+ Placebo dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose1 + placebo dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 tablets、Placebo</intervention_name>
    <description>SHR0302 tablets dose 1 for 48 weeks</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 tablets、Placebo</intervention_name>
    <description>SHR0302 tablets dose 2 for 48 weeks</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed informed consent；&#xD;
&#xD;
          2. Diagnosis of PsA fulfillment of the Classification Criteria for PsA (CASPAR) criteria&#xD;
             with symptom onset at least 6 months prior to the Screening Visit；&#xD;
&#xD;
          3. Active arthritis at screening/baseline as indicated by &gt;/= 3 tender/painful and 3&#xD;
             swollen joints；&#xD;
&#xD;
          4. Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other autoimmune diseases; history of cancer or infection including&#xD;
             tuberculosis and hepatitis; history of important cardiovascular events or thrombotic&#xD;
             diseases；&#xD;
&#xD;
          2. Non-plaque forms of psoriasis (with exception of nail psoriasis)；&#xD;
&#xD;
          3. Previous treatment with cytotoxic drugs; JAK inhibitor or bDMARDs within 6 months of&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YuXian Zhu</last_name>
    <phone>15901802096</phone>
    <email>yuxian.zhu@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuoli Zhang, Doctor</last_name>
      <phone>+86-13901094780</phone>
      <email>zhuoli.zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

